Author

Michela Robusto

IFOMORCID 0000-0001-7673-165XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Approach:statistical model· 1

Frequent Co-Authors

Adrian AndronacheiD· 2 shared Ciro MercurioiD· 2 shared Mario VarasiiD· 2 shared Alberto J. ArribasiD· 1 shared Alessandra TucciiD· 1 shared Alex ZadroiD· 1 shared Anastasios StathisiD· 1 shared Andrea RinaldiiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Adrian AndronacheORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 25, 2025

High-Throughput Screening Identifies PLK1 Inhibition as a Strategy to Potentiate BTK Blockade in Marginal Zone Lymphoma

Alex Zadro, Alberto J. Arribas, Michela Robusto…·Francesco Bertoni

This study identifies PLK1 inhibition as a strategy to enhance BTK blockade in MZL by overcoming resistance through transcriptomic and mechanistic analysis.

DOI 10.1101/2025.10.25.684506

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyBlood Cancer DiscoveryPeer-reviewedMay 22, 2025

B cell receptor silencing reveals the origin of high-grade B cell lymphomas with MYC and BCL2 rearrangements

Gabriele Varano, Silvia Lonardi, Paola Sindaco…·Stefano S Casola

This paper shows that high-grade B cell lymphomas with MYC and BCL2 rearrangements originate from BCR-silenced follicular lymphoma cells that acquire IGL::MYC translocations, leading to resistance to CD79B-targeting therapy.

10 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky